JP2018520197A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520197A5
JP2018520197A5 JP2018502670A JP2018502670A JP2018520197A5 JP 2018520197 A5 JP2018520197 A5 JP 2018520197A5 JP 2018502670 A JP2018502670 A JP 2018502670A JP 2018502670 A JP2018502670 A JP 2018502670A JP 2018520197 A5 JP2018520197 A5 JP 2018520197A5
Authority
JP
Japan
Prior art keywords
hepe
composition
subject
cancer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018502670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520197A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/001140 external-priority patent/WO2017013492A1/en
Publication of JP2018520197A publication Critical patent/JP2018520197A/ja
Publication of JP2018520197A5 publication Critical patent/JP2018520197A5/ja
Priority to JP2021064536A priority Critical patent/JP2021107406A/ja
Pending legal-status Critical Current

Links

JP2018502670A 2015-07-21 2016-07-21 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物 Pending JP2018520197A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021064536A JP2021107406A (ja) 2015-07-21 2021-04-06 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195138P 2015-07-21 2015-07-21
US62/195,138 2015-07-21
PCT/IB2016/001140 WO2017013492A1 (en) 2015-07-21 2016-07-21 Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064536A Division JP2021107406A (ja) 2015-07-21 2021-04-06 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物

Publications (2)

Publication Number Publication Date
JP2018520197A JP2018520197A (ja) 2018-07-26
JP2018520197A5 true JP2018520197A5 (https=) 2019-09-05

Family

ID=56852299

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018502670A Pending JP2018520197A (ja) 2015-07-21 2016-07-21 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
JP2021064536A Pending JP2021107406A (ja) 2015-07-21 2021-04-06 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021064536A Pending JP2021107406A (ja) 2015-07-21 2021-04-06 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物

Country Status (6)

Country Link
US (3) US20170020836A1 (https=)
EP (2) EP3325094B1 (https=)
JP (2) JP2018520197A (https=)
CN (2) CN112245420A (https=)
ES (1) ES2851525T3 (https=)
WO (1) WO2017013492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
KR20220163468A (ko) * 2020-04-03 2022-12-09 애피뮨 리미티드 혈액학적 장애 및/또는 관련 질환을 치료 또는 예방하기 위한 15-hepe를 포함하는 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
KR20050083960A (ko) 2002-11-22 2005-08-26 닛폰 스이산 가부시키가이샤 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
AU2011253846A1 (en) * 2004-11-19 2012-01-12 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Similar Documents

Publication Publication Date Title
JP2018520197A5 (https=)
JP2016536286A5 (https=)
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
JP2019519519A5 (https=)
MX2017011836A (es) Terapia de combinacion optimizada y uso de la misma para tratar cancer y enfermedad autoinmunitaria.
JP2016538271A5 (https=)
CN104109193B (zh) 一种抗癌活性肽变体及其应用
JP2012041365A5 (https=)
NZ723271A (en) Fused imidazole derivatives useful as ido inhibitors
JP2015528471A5 (https=)
JP2010270124A5 (https=)
JP2017533221A5 (https=)
JP2019510075A5 (https=)
JP2018537513A5 (https=)
CN110546150A (zh) 含吡唑基的三并环类衍生物、其制备方法和应用
JP2014530181A5 (https=)
JP2013544892A5 (https=)
CN109311893A (zh) 含有取代环戊基的吡咯并嘧啶化合物
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
El Sharouni et al. Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer
WO2019103449A3 (ko) 항암바이러스의 간동맥 투여를 이용한 간암 치료방법
CA2489705A1 (en) Use of amide derivative of ge 2270 factor a3 for the treatment of acne
FR2956325B1 (fr) Radiomarquage stable a dose therapeurique au rhenium-188, et automatisation de celui-ci, en particulier pour le traitement du cancer du foie
JP2015516464A5 (https=)